Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Non-Current Assets (2017 - 2025)

Autolus Therapeutics (AUTL) has disclosed Non-Current Assets for 9 consecutive years, with $146.7 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Non-Current Assets rose 54.42% year-over-year to $146.7 million, compared with a TTM value of -$252.2 million through Jun 2025, down 164.93%, and an annual FY2024 reading of $121.8 million, up 21.7% over the prior year.
  • Non-Current Assets was $146.7 million for Q2 2025 at Autolus Therapeutics, up from -$615.8 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $146.7 million in Q2 2025 and bottomed at -$615.8 million in Q1 2025.
  • Average Non-Current Assets over 5 years is -$9.5 million, with a median of $95.3 million recorded in 2023.
  • The sharpest move saw Non-Current Assets plummeted 39.74% in 2021, then skyrocketed 136.93% in 2023.
  • Year by year, Non-Current Assets stood at $58.6 million in 2021, then rose by 10.06% to $64.5 million in 2022, then surged by 55.15% to $100.1 million in 2023, then rose by 21.7% to $121.8 million in 2024, then grew by 20.47% to $146.7 million in 2025.
  • Business Quant data shows Non-Current Assets for AUTL at $146.7 million in Q2 2025, -$615.8 million in Q1 2025, and $121.8 million in Q4 2024.